Core Insights - 4basebio PLC is expanding its operations with a new innovation hub and manufacturing facility in Cambridge, UK, to meet the increasing demand for synthetic DNA in next-generation therapeutics [2][6] Company Expansion - The new facility will be approximately 26,500 square feet, including 7,500 square feet of specialized laboratory space with 15 labs equipped with advanced biosafety cabinets and state-of-the-art air handling systems [4] - The facility is expected to be operational by late summer 2026, following its development [3] Industry Demand - There is a growing demand for high-quality synthetic DNA, particularly for mRNA vaccines and cell and gene therapies, as personalized medicine continues to advance [6] - Synthetic DNA offers advantages over plasmid DNA in terms of purity, safety, and scalability, which is critical as development pipelines mature [6] Company Commitment - The CEO of 4basebio emphasized the company's commitment to providing high-quality synthetic DNA to support the advancement of genomic therapies and vaccine development [8] - The new facility is positioned to enhance the company's ability to support customers through clinical phases of drug development [8]